Overview

Useful For
An aid in the diagnosis of recent or past *Treponema pallidum* infection

Routine prenatal screening

This test is **not useful** for diagnosis of congenital syphilis.

This test is **not offered** as a screening or confirmatory test for blood donor specimens.

**Highlights**

This testing should be used to assess for recent or past infection with *Treponema pallidum* or for routine prenatal screening.

Testing for syphilis is performed using the reverse screening algorithm at Mayo Clinic and Mayo Clinic Laboratories.

**Method Name**

Multiplex Flow Immunoassay

**NY State Available**

Yes

**Specimen**

**Specimen Type**

Serum

**Specimen Required**

**Collection Container/Tube:** Serum gel

**Acceptable:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 0.5 mL

**Collection Instructions:** Centrifuge and aliquot serum

**Forms**

If not ordering electronically, complete, print, and send a [Microbiology Test Request](#) (T244) with the specimen.

**Specimen Minimum Volume**

0.4 mL

**Reject Due To**

<table>
<thead>
<tr>
<th>Gross hemolysis</th>
<th>Reject</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross lipemia</td>
<td>Reject</td>
</tr>
</tbody>
</table>
Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td>Refrigerated (preferred)</td>
<td>14 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frozen</td>
<td>14 days</td>
<td></td>
</tr>
</tbody>
</table>

Clinical and Interpretive

Clinical Information

Syphilis is a disease caused by infection with the spirochete Treponema pallidum. The infection is systemic and the disease is characterized by periods of latency. These features, together with the fact that T pallidum cannot be isolated in culture, mean that serologic techniques play a major role in the diagnosis and follow-up of treatment for syphilis.

Historically, the serologic testing algorithm for syphilis included an initial non-treponemal screening test, such as the rapid plasma reagin (RPR) or the Venereal Disease Research Laboratory (VDRL) tests. Because these tests measure the host's antibody response to non-treponemal antigens, they lack specificity. Therefore, a positive result by RPR or VDRL requires confirmation by a treponemal-specific test, such as the fluorescent treponemal antibody-absorbed (FTA-ABS) or microhemagglutination assay (MHA-TP). Although the FTA-ABS and MHA-TP are technically simple to perform, they are labor intensive and require subjective interpretation by testing personnel.

As an alternative to the traditional syphilis screening algorithm as described above, many laboratories utilize the reverse syphilis screening algorithm. This algorithm starts with an automated treponemal assay, such as an enzyme immunoassay (EIA) and multiplex flow immunoassay (MFI), to detect antibodies specific to T pallidum. If the screening assay is positive, the sample is reflexed to a RPR assay, which if positive is reported with a titer and is indicative of active or recent syphilis infection. If the RPR is negative, the sample is reflexed to a second treponemal assay, such as the T pallidum particle agglutination (TPPA) assay. If the TPPA is positive, this would indicate previously treated or late stage syphilis infection. Alternatively, if the TPPA is negative, the initial positive screen is interpreted as a false positive result.

Syphilis screening at Mayo Clinic is performed by using the reverse algorithm, which first tests sera for Treponema pallidum specific IgG/IgM antibodies using an automated MFI. A positive treponemal test suggests infection with T pallidum, but does not distinguish between recent or past, or treated and untreated infection. This is because treponemal tests may remain reactive for life, even following adequate therapy. Therefore, the results of a nontreponemal assay, such as RPR, are needed to provide information on a patient's disease state and history of therapy. (Table 1)

In some patients, the results of the treponemal screening test and RPR may be discordant (eg, syphilis IgG/IgM positive and RPR negative). To discriminate between a falsely reactive screening result and past syphilis, a second treponemal-specific antibody test is recommended using a method that is different from the initial screen test (eg, T pallidum particle agglutination: TP-PA).

In the setting of a positive syphilis IgG/IgM screening result and a negative RPR, a positive TP-PA result is
consistent with either 1) past, successfully treated syphilis, 2) early syphilis with undetectable RPR titers, or 3) late/latent syphilis in patients who do not have a history of treatment for syphilis. Further historical evaluation is necessary to distinguish between these scenarios. (Table 1)

In the setting of a positive syphilis IgG/IgM screening result and a negative RPR, a negative TP-PA result is most consistent with a falsely reactive syphilis IgG/IgM screen. (Table 1) If syphilis remains clinically suspected, a second specimen should be submitted for testing.

Table 1. Interpretation and follow-up of reverse screening results:

<table>
<thead>
<tr>
<th>Patient history</th>
<th>Syphilis Total Ab by MFI</th>
<th>RPR</th>
<th>TP-PA</th>
<th>Interpretation</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown history of syphilis</td>
<td>Nonreactive</td>
<td>NA</td>
<td>NA</td>
<td>No serologic evidence of syphilis</td>
<td>None, unless clinically indicated (eg, early/acute/primary syphilis)</td>
</tr>
<tr>
<td>Unknown history of syphilis</td>
<td>Reactive</td>
<td>Reactive</td>
<td>NA</td>
<td>Untreated or recently treated syphilis</td>
<td>See CDC treatment guidelines</td>
</tr>
<tr>
<td>Unknown history of syphilis</td>
<td>Reactive</td>
<td>Nonreactive</td>
<td>Nonreactive</td>
<td>Probable false-positive screening test</td>
<td>No follow-up testing, unless clinically indicated (eg, acute/primary syphilis)</td>
</tr>
<tr>
<td>Unknown history of syphilis</td>
<td>Reactive</td>
<td>Nonreactive</td>
<td>Reactive</td>
<td>Possible syphilis (eg, early or latent) or previously treated syphilis</td>
<td>Historical and clinical evaluation required</td>
</tr>
<tr>
<td>Unknown history of syphilis</td>
<td>Equivocal</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Unknown history of syphilis</td>
</tr>
<tr>
<td>Known history of syphilis</td>
<td>Reactive</td>
<td>Nonreactive</td>
<td>Reactive or NA</td>
<td>Past, successfully treated syphilis</td>
<td>None</td>
</tr>
</tbody>
</table>

MFI, multiplex flow immunoassay; NA, not applicable; RPR, rapid plasma reagin; TP-PA, *Treponema pallidum* particle agglutination

www.cdc.gov/std/treatment/2010/

Reference Values

Nonreactive

**Interpretation**

Nonreactive:
No serologic evidence of exposure to *Treponema pallidum* (syphilis). Repeat testing may be considered in patients with suspected acute or primary syphilis.

Equivocal:

Recommend follow-up testing in 10 to 14 days if clinically indicated.

Reactive:

Results suggest infection with *T pallidum* at some point in time. Results do not distinguish between recent or past infection, or between treated and untreated syphilis as treponema-specific IgG may remain elevated despite appropriate therapy. Falsely reactive treponemal results may occur; additional testing by a non-treponemal assay is recommended if not previously performed on this sample.

**Cautions**

Despite active syphilis, serologic tests may be negative in severely immunosuppressed patients such as those with AIDS.

In very early cases of primary syphilis, serology tests for syphilis may be negative.

In cases of untreated, late or latent syphilis, the result of rapid plasma reagin may be negative. However, the syphilis screening test multiplex flow immunoassay (MFI) and *Treponema pallidum* particle agglutination (TP-PA) should be positive. A thorough clinical and historical evaluation should be performed to determine if treatment for latent syphilis is required.

Results should be considered in the context of all available clinical and laboratory data.

**Clinical Reference**

1. CDC. Discordant results from reverse sequence syphilis screening-five laboratories, United States, 2006-2010. Morb Mortal WKLY Rep 2011;60(5):133-137


**Performance**

**Method Description**

The BioPlex 2200 Syphilis Total and RPR kit employs *Treponema pallidum* fusion protein (rTP47/rTP17) and cardiolipin antigen-coated fluoromagnetic beads with unique fluorescent signatures to identify the presence of IgG and IgM antibodies to *Treponema pallidum* and nontreponemal reagin antibodies in a 2-step assay format. Dyed beads are coated with recombinant *T pallidum* rTP47/rTP17 fusion protein or cardiolipin antigen. The BioPlex 2200 System combines an aliquot of patient sample, sample diluent and bead reagent into a reaction vessel. The mixture is incubated at 37 degrees C. After a wash cycle, a mixture of murine monoclonal anti-human IgG and murine monoclonal anti-human IgM antibody conjugated to phycoerythrin (PE) is added to the dyed beads, and this mixture is incubated at 37 degrees C. The excess conjugate is removed in another wash cycle and the beads are re-suspended in wash buffer. The bead mixture then passes through the detector. The identity of the dyed beads is determined by the fluorescence of the dyes, and the amount of antibody captured by the antigen is determined by the fluorescence of the attached PE. Raw data is calculated in relative fluorescence intensity (RFI). (BioPlex 2200 Document generated April 12, 2020 at 5:10pm CDT)
Test Definition: SYPHN
Syphilis Total Ab, S

PDF Report
No

Day(s) and Time(s) Test Performed
Monday through Saturday; 9 a.m.

Analytic Time
Same day/1 day

Maximum Laboratory Time
2 days

Specimen Retention Time
14 days

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
86780

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYPHN</td>
<td>Syphilis Total Ab, S</td>
<td>47236-5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYPHN</td>
<td>Syphilis Total Ab, S</td>
<td>47236-5</td>
</tr>
</tbody>
</table>